Sustainable PFAS-free synthesis for pharmaceutical compounds
The novel, environmentally-friendly synthesis strategy holds potential for manufacturing scale up, according to the research.
List view / Grid view
The novel, environmentally-friendly synthesis strategy holds potential for manufacturing scale up, according to the research.
This article discusses the impact of the recent mpox emergency following the outbreak of the virus in 2022, highlights the industry’s response, potential vaccine candidates and key recommendations for international management of the disease.
The first-of-a-kind investment supports the UK government’s objectives to boost clinical trials, improve patient access to novel treatments and increase competitiveness in life sciences.
The planned expansion is set to strengthen AstraZeneca’s capability to manufacture biologic medicines for patients globally.
The method has potential in both biomanufacturing and production of autologous cell therapies, the research suggests.
The new member of Genmab’s Executive Committee brings over 30 years of international biopharmaceutical experience to the role.
The paper presents an “efficient and scalable GMP-compliant process” for purifying a fusogenic oncolytic virus (rVSV-NDV).
The planned €1.3 billion investment will result in the new German facility replacing the company’s existing insulin production plants.
Utilising a digital twin for an advanced process control strategy facilitates additional productivity gains of 20 percent at 99.9 percent reliability, the authors shared.
Inauguration of the new facility supports BeiGene’s goal to develop affordable and accessible cancer treatments for patients globally.
European Pharmaceutical Review's latest Pharma Horizons report provides insight on key developments within pharmaceutical drug formulation for drug development, pharmaceutical manufacturing and quality control.
The report insists that to take advantage of the expected surge in RNA-based therapeutics, it is imperative to secure a sufficiently trained workforce in the UK.
CO2 emissions produced by the energy generated at Boehringer Ingelheim's site are reduced by over half with the new biomass power plant.
Single-temperature incubation has been discussed for a long time in the pharmaceutical industry but only a few sites have implemented this system. Here, Guillaume Pinon, Head of the Microbiology Lab at Servier, discusses the use of single-temperature incubation in an aseptic production facility, outlining the regulatory considerations, strategic approach, challenges…
Continuous chemical manufacturing technology has been in use for more than 100 years producing high-volume commodity chemicals. However, it was not until the early 2000s that the technology caught the attention of the pharmaceutical industry in a significant way.